布地奈德/福莫特罗维持缓解治疗与固定剂量氟替卡松/沙美特罗在COPD患者中的比较
该研究纳入195例过去2年至少1次急性加重的COPD患者,随机接受开放标签的布地奈德/福莫特罗维持缓解治疗(MART)或固定剂量氟替卡松/沙美特罗治疗1年。结果显示两组中重度急性加重率无显著差异(1.32 vs 1.32/年,率比1.05,95%CI 0.79-1.39,p=0.741),肺功能及健康状况无差异,但MART组每日吸入激素剂量显著更低(布地奈德等效928 µg/天 vs 1747 µg/天,p<0.05)。
要点
- COPD患者中MART与固定剂量FSC的中重度急性加重率无显著差异。
- MART组每日吸入激素剂量显著低于FSC组。
- 两组不良事件及肺炎发生率相似,长期安全性需进一步证据。
核心结论
- 在COPD患者中,布地奈德/福莫特罗MART可能与传统固定剂量氟替卡松/沙美特罗治疗同样有效,且每日吸入激素剂量更低。
- 需要进一步证据评估长期安全性。
研究设计与样本
- 随机、开放标签研究,纳入过去2年至少1次急性加重的COPD患者195例。
- 患者随机分为MART组(布地奈德/福莫特罗160/4.5 µg,每日2吸,按需1吸,n=103)或固定剂量FSC组(氟替卡松/沙美特罗500/50 µg,每日1吸,按需沙丁胺醇100 µg,n=92),治疗1年。
- 主要结局为中重度急性加重率(需口服泼尼松龙和/或抗生素治疗)。
主要发现
- MART组与FSC组中重度急性加重率分别为1.32/年和1.32/年,率比1.05(95%CI 0.79-1.39),p=0.741。
- 两组肺功能参数及健康状况无差异。
- MART组每日吸入激素剂量(布地奈德等效928 µg/天)显著低于FSC组(1747 µg/天),p<0.05。
- 不良事件发生率MART组73%、FSC组68%(p=0.408);肺炎发生率MART组5%、FSC组1%(p=0.216)。
临床怎么用
- 对于有急性加重史的COPD患者,可考虑使用布地奈德/福莫特罗MART作为固定剂量ICS/LABA治疗的替代方案,以降低吸入激素剂量。
- 需关注长期安全性,尤其是肺炎风险。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(195例),长期安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintenance and reliever therapy (MART) with inhaled corticosteroid (ICS)/formoterol effectively reduces exacerbations in asthma. We aimed to investigate its efficacy compared with fixed-dose fluticasone/salmeterol in chronic obstructive pulmonary disease (COPD). METHODS: Patients with COPD and ≥1 exacerbation in the previous 2 years were randomly assigned to open-label MART (Spiromax budesonide/formoterol 160/4.5 µg 2 inhalations twice daily+1 prn) or fixed-dose therapy (Diskus fluticasone propionate/salmeterol combination (FSC) 500/50 µg 1 inhalation twice daily+salbutamol 100 µg prn) for 1 year. The primary outcome was rate of moderate/severe exacerbations, defined by treatment with oral prednisolone and/or antibiotics. RESULTS: In total, 195 patients were randomised (MART Bud/Form n=103; fixed-dose FSC n=92). No significant difference was seen between MART and FSC therapy in exacerbation rates (1.32 vs 1.32 /year, respectively, rate ratio 1.05 (95% CI 0.79 to 1.39); p=0.741). No differences in lung function parameters or health status were observed. Total ICS dose was significantly lower with MART than FSC therapy (budesonide-equivalent 928 µg/day vs 1747 µg/day, respectively, p<0.05). Similar proportions of patients reported adverse events (MART Bud/Form: 73% vs fixed-dose FSC: 68%, p=0.408) and pneumonias (MART: 5% vs FSC: 1%, p=0.216). CONCLUSIONS: This first study of MART in COPD found that budesonide/formoterol MART might be similarly effective to fluticasone/salmeterol fixed-dose therapy in moderate to severe patients with COPD, at a lower daily ICS dosage. Further evidence is needed about long-term safety.
引用
- Muiser, Imkamp, Seigers, et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023. PMID: 36725331. doi:10.1136/thorax-2022-219620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。